Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab maintenance and open-label extension study in ulcerative colitis
NL-OMON54535Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of risankizumab in autoimmune colitis (5 arms), sponsored by AbbVie Inc. Primary endpoints: Clinical remission at Week 52 and Long-term safety. Started May 2019; status: recruiting.
02
Drugs
risankizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON54535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54535.